Lexaria Bioscience Corp. (Nasdaq: LEXX) announced that dosing has commenced on schedule in its Human Pilot Study #7 (GLP-1-H26-7), a five-week trial evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's commercially available Wegovy® tablets. The study, which began on June 14, 2026, is fully funded from existing corporate resources.
The study is designed to assess safety, tolerability, and pharmacokinetic properties of Lexaria's formulations. It includes three arms: two DehydraTECH-semaglutide compositions—one in tablet form and one in capsule—both containing salcaprozate sodium (SNAC), and a control arm using Wegovy® tablets. This is the first time Lexaria has tested a tablet formulation in its GLP-1 studies, aiming to mimic the physical properties of Novo's Rybelsus® and Wegovy® tablets, which temporarily adhere to the stomach lining to optimize absorption.
Lexaria's previous single-dose studies (GLP-1-H24-1 and GLP-1-H24-2) demonstrated that its SNAC-inclusive DehydraTECH-semaglutide formulations matched or exceeded the pharmacokinetic performance of Rybelsus® and showed favorable safety profiles. However, those were single-dose studies of shorter duration. The current study extends to five weeks to achieve steady-state concentration levels, where drug input balances with natural elimination.
The results are expected to be closely reviewed by the pharmaceutical industry, potentially leading to commercial partnerships leveraging Lexaria's DehydraTECH technology. The company aims to preserve the enhanced safety and tolerability seen in earlier studies while achieving pharmacokinetic performance comparable to or better than Wegovy® tablets.
DehydraTECH™ is Lexaria's patented drug delivery platform that improves oral drug absorption, reduces side effects, and facilitates blood-brain barrier penetration. The company holds 66 granted patents and operates a licensed in-house research laboratory. More information is available at www.lexariabioscience.com.
